Anti-UL42 antibody [13C9]

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

UL42 also known as UL42 processivity factor is a DNA polymerase accessory protein found in herpes simplex virus (HSV). It plays an important role in the replication of viral DNA by binding to the DNA polymerase. UL42 has a molecular weight of approximately 65 kilodaltons and expresses in infected cells during the lytic cycle. Its primary function is to increase the processivity of the DNA polymerase enzyme allowing for efficient viral DNA synthesis. UL42 achieves this by attaching tightly to the DNA providing a clamp-like function for the polymerase.

Biological function summary

The UL42 protein interacts with the HSV DNA polymerase to form a complex critical for replication. The complex stabilizes the polymerase-DNA interaction significantly enhancing the polymerase's ability to synthesize long strands of DNA without detaching. The persistence of the complex is essential for continuous and efficient viral replication which is an important aspect of the herpes virus's ability to maintain infection in the host.

Pathways

The role of UL42 in DNA replication situates it within the viral replication pathways. It specifically contributes to the HSV lifecycle by ensuring the viral genome is copied efficiently. UL42 interacts particularly with the UL30 protein the catalytic subunit of the viral DNA polymerase. This interaction is important within the replication fork structure which is a significant aspect of HSV-specific viral replication pathways. The concerted action of UL42 and UL30 ensures that the viral DNA synthesis process is completed successfully.

UL42 is closely related to herpes simplex infections which can lead to conditions such as cold sores and genital herpes. The efficiency of viral replication driven by the UL42 and UL30 complex plays a direct role in disease progression and symptom manifestation. Understanding the function of UL42 can aid in developing targeted therapies which aim to disrupt this interaction and consequently reduce viral replication and disease severity.